Result for
Topic: Vaccines and Immunity
January 27, 2021
Kinetics and Correlates of the Neutralizing Antibody Response to SARS-CoV-2Kinetics and Correlates of the Neutralizing Antibody Response to SARS-CoV-2Kinetics and Correlates of the Neutralizing Antibody Response to SARS-CoV-2
[Pre-print, not per-reviewed] A longitudinal study of people who had recovered from COVID-19 (n=963) estimated a half-life of 7.7 months for anti-spike IgG and a half-life of 8.7 months for serum neutralization, with only 13% of individuals losing seroreactivity at ten months. In addition, around 3% of recovered patients demonstrated effective cross-neutralizing IgG antibodies to…
Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
[Pre-print, not per-reviewed] The SARS-CoV-2 variant B.1.1.7 (UK) was resistant to neutralization by several monoclonal antibodies (mAbs) targeting either the N-terminal domain (NTD) of the virus’s spike protein or its receptor-binding domain (RBD). This variant was also modestly more resistant to neutralization with convalescent plasma (about 3 fold) and sera from people who had received…
January 26, 2021
Longitudinal Analysis of Humoral Immunity against SARS-CoV-2 Spike in Convalescent Individuals up to 8 Months Post-Symptom Onset
[Pre-print, not peer-reviewed] A longitudinal study of 101 blood samples from 32 people recovering from COVID-19 found that memory B cells for anti-receptor binding domain (RBD) IgG antibodies increase over time and persist for up to 8 months post-symptom onset. Detectable IgG and sustained Fc-effector activity in plasma was also observed up to 8 months,…
January 25, 2021
SARS-CoV-2 Reinfection in a Cohort of 43,000 Antibody-Positive Individuals Followed for up to 35 Weeks
[Pre-print, not peer-reviewed] A study of SARS-CoV-2 reinfection in Qatar found that reinfection was rare, and that natural infection elicited strong antibody response with at least 90% efficacy lasting at least 7 months. Among study participants (n = 314) with at least one PCR positive swab ≥14 days after the first-positive antibody test, 129 (41.1%)…
MRNA-1273 Vaccine Induces Neutralizing Antibodies against Spike Mutants from Global SARS-CoV-2 Variants
[Pre-print, not peer-reviewed] Sera from human subjects or non-human primates (NHPs) that received the mRNA-1273 (Moderna) vaccine showed no significant reduction in neutralization activity against the SARS-CoV-2 B.1.1.7 variant emerging from the UK, but reduced activity against the B.1.351 variant emerging from South Africa. The study used two pseudovirus neutralization assays expressing spike proteins of…
The Potential Public Health and Economic Value of a Hypothetical COVID-19 Vaccine in the United States: Use of Cost-Effectiveness Modeling to Inform Vaccination Prioritization
A Markov cohort model estimating COVID-19 related direct medical costs and deaths in the US found that with a SARS-CoV-2 vaccine with 60% efficacy, the incremental cost per quality-adjusted life-year (QALY) gained for the US adult population would be $8,200 (compared to no vaccination). For those at high risk of hospitalization and death, vaccination was…
Assessment of U.S. Health Care Personnel (HCP) Attitudes towards COVID-19 Vaccination in a Large University Health Care System
Self-reported willingness to receive the COVID-19 vaccine differed by hospital role among US healthcare workers (n=5287), with physicians and research scientists reporting the highest acceptance (80.4%). 33.6% of registered nurses, 31.6% of allied health professionals, and 32% of master’s level clinicians were unsure if they would get the vaccine. Fewer direct care (54.0%) than non-care…
January 22, 2021
Effective Virus-Neutralizing Activities in Antisera from the First Wave of Severe COVID-19 Survivors
A serological study of specimens from 104 people who survived severe COVID-19 infections demonstrated that neutralizing antibodies to SARS-CoV-2 persisted for at least six months. Researchers also found that although IgG levels among severe COVID-19 patients at the convalescent phase were generally lower compared to those at the acute phase, the antibodies in serum from…
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine
CDC identified 21 case reports of anaphylaxis during the administration of a reported 1,893,360 first doses of Pfizer-BioNTech COVID-19 vaccine between December 14 and 23, 2020. Of these 21 cases, four people (19%) were hospitalized and 17 (81%) were treated in emergency departments. No deaths from anaphylaxis were reported. Seventeen (81%) of 21 patients with…
Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine — United States, December 21, 2020–January 10, 2021
Between December 21, 2020 and January 10, 2021, monitoring by the Vaccine Adverse Event Reporting System detected ten cases of anaphylaxis after administration of a reported 4,041,396 first doses of the Moderna COVID-19 vaccine in the US. In nine cases, onset occurred within 15 minutes of vaccination. Nine of the ten cases of anaphylaxis occurred…
Previous page Next page